To Top

Community

Emilie Branch

Emilie is responsible for strategic content development based on scientific areas of specialty for Nice Insight research articles and for assisting client content development across a range of industry channels. Prior to joining Nice Insight, Emilie worked at a strategy-based consulting firm focused on consumer ethnographic research. She also has experience as a contributing editor, and has worked as a freelance writer for a host of news and trends-related publications

Contribution
Approval

Genentech Receives Additional Approval for Tecentriq

PAO-M12-18-NI-011
Growth

WuXi AppTec Plans for Growth

PAO-M12-18-NI-005-10
FDA

FDA Gives Novartis Gene Replacement Therapy Application Priority Review

PAO-M12-18-NI-003
Clinical Study

Clinical Study Explores the Efficacy of Numerous Ebola Therapies

PAO-M11-18-NI-029
Facility

WuXi Biologics Breaks Ground on Innovation Center in China

PAO-M11-18-NI-026
Oncology

Radiotherapy Makes a Comeback

PAO-M11-18-NI-023
Immunotherapy

Patient Weight Can Impact the Effectiveness of Cancer Immunotherapies

PAO-M11-18-NI-022
Drug Development

EMA Recommends Approval of the First Oral Drug for Sleeping Sickness

PAO-M11-18-NI-019
FDA Approval

US FDA Approves Third Pfizer Cancer Drug in Two Months

PAO-M11-18-NI-014
New Facility

GSK Opens New Facility in Scotland

PAO-M11-18-NI-007
Osteoarthritis

High-Valued Start-Up Announces Positive Results for Osteoarthritis Drug

PAO-M11-18-NI-003
FDA Approval

GSK’s ViiV Healthcare Seeks FDA Approval for Combination HIV Therapy

PAO-M10-18-NI-029
Generics

FDA Looking for Way to Facilitate Simultaneous Generic Approvals

PAO-M10-18-NI-027
Big Data

Big Data in Drug Packaging and Distribution

PAP-Q4-18-NI-004
Investment

Foreign Investment: Chinese Capital Backs U.S. Biotech

PAP-Q4-18-NI-008
Pharma Marketing

Pharma’s Big Spending on TV Ads Continues in 2018

PAO-M10-18-NI-022
FDA

FDA Gives De Novo Clearance to First Over-the-Counter Hearing Aid

PAO-M10-18-NI-015
Artificial Intelligence

UK Hospital to Get Command Center Driven by AI and Real-Time Analytics

PAO-M10-18-NI-013
FDA Approval

New Treatment Option for Migraine Suffers

PAO-M10-18-NI-005
Immunotherapy

Nobel Prize in Medicine Goes to Immunotherapy Developers

PAO-M10-18-NI-003
Investment

The Biotech Boom

PAP-Q3-18-NI-003
Clinical Results

Fish-Oil Drug Shows Dramatic Results in Cardiovascular Study

PAO-M09-18-NI-025
Research

New Evidence Suggests the Brain and Stomach are in Direct Communication

PAO-M09-18-NI-023
Stem-Cell

Stem Cell Research May Lead to Treatments for Gastrointestinal Diseases

PAO-M09-18-NI-019
Acquisition

Allergan Makes Neurotoxin Buy with Acquisition of Bonti Inc.

PAO-M09-18-NI-015
Breakthrough Therapy

Breakthrough Therapy Designation for New Asthma Drug

PAO-M09-18-NI-008
Drug Development

Bayer Gets FDA Approval for Hemophilia A Drug

PAO-M09-18-NI-006
Drug Development

Funding Raised for Development of Drug to Treat Symptoms of Menopause

PAO-M09-18-NI-004
FDA Guidance

FDA Published Draft Guidance on Use of Placebo Control Groups

PAO-M08-18-NI-029
Research

Researchers Make Discovery about Leptin Resistance

PAO-M08-18-NI-025
Acquisition

Quethera Acquired by Astellas Pharma

PAO-M08-18-NI-018
Investment

Artios Pharma Receives $84 million in Series B Funding

PAO-M08-18-NI-014
Biologics

New Method Developed for Stereoselective Synthesis of Biologic Drug Substances

PAO-M08-18-NI-011
Microbiome

New Collaboration Targets Drug Development Using the Gut Microbiome

PAO-M08-18-NI-007
FDA

New Weekly Dose of Tafenoquine Gets Favorable Vote from FDA Advisory Committee

PAO-M08-18-NI-005
Drug Development

Novartis Will Spend Up to More Than $1 Billion on an Eczema Candidate

PAO-M07-18-NI-017
Drug Development

Appeals Board Rules in Favor of Novartis and its Multiple Sclerosis Drug Gilenya

PAO-M07-18-NI-014
Drug Development

New Antibiotic to be Tested against Potential Bioweapons

PAO-M07-18-NI-009
Advertising

Digital Ad Spending by Pharma is Growing Slowly

PAO-M07-18-NI-008
Opioids

Gottlieb Discusses Results of Online Opioid Summit

PAO-M07-18-NI-003
Drug Delivery

Automated Insulin Delivery System Approved for Use by More Pediatric Patients

PAO-M06-18-NI-023
Microbiome

Kaleido Raises More Money for Development of Microbiome-Based Therapeutics

PAO-M06-18-NI-021
Antiviral

Progress on New Antiviral Drugs at Chimerix

PAO-M06-18-NI-019
CRISPR

New Diagnostic Tool for Heart Disease Based on CRISPR Technology

PAO-M06-18-NI-016
Drug Discovery

Could a Bispecific Antibody Be A Functional Cure for AIDS?

PAO-M06-18-NI-015
Oncology

Hormone Therapy Appears to Be the Best Bet for Treating Early Breast Cancer

PAO-M06-18-NI-011
Opiods

Preliminary Data Suggests DENKI Pain Blockers Don’t Have Abuse Potential

PAO-M06-18-NI-008
Biosimilars

Another mAb Biosimilar on the Horizon in Europe

PAO-M06-18-NI-006
FDA

FDA Announces Policies to Facilitate Development of Generic Drugs

PAO-M06-18-NI-004
Inhalation

GSK Applies in Japan for Approval of a Once-Daily, Single Inhaler Triple Therapy for COPD

PAO-M05-18-NI-022
Fast Track

Valneva Receives Fast Track Designation for Lyme Disease Vaccine

PAO-M05-18-NI-021
FDA Approval

New Treatment for Management of Opioid Withdrawal Symptoms Approved by FDA

PAO-M05-18-NI-019
Drug Development

Bacteria in the Stomach Found to Play a Role in Multiple Sclerosis

PAO-M05-18-NI-016
Diagnostics

Researchers Develop Diagnostic for Rare Cancer-Generated Glycoproteins

PAO-M05-18-NI-012
Cell and Gene Therapy

Editas Founders Start New Gene Editing Company

PAO-M05-18-NI-011
Oncology

Roche’s TECENTRIQ (Atezolizumab) Receives Priority Review

PAO-M05-18-NI-009
Acquisition

Takeda Acquires Shire for $62 Billion

PAO-M05-18-NI-005
Collaboration

Collaboration Intends to Improve Multidisciplinary Teaching and Research in Biotech

PAO-M04-18-NI-023
Patient Adherence

New Approach by Novo Nordisk Ties Pricing to Patient Behavior

PAO-M04-18-NI-017
Innovation

Robotic Microscope Used for Brain Surgery

PAO-M04-18-NI-014
Oncology

New Breast Cancer Drug Accepted for Review by EMA

PAO-M04-18-NI-010
Approval

Amgen Gets Expanded Approval for Blincyto®

PAO-M04-18-NI-005
Results

Positive Results for Pfizer Drug Tafamidis

PAO-M04-18-NI-001
Probiotics

J&J Involved in Probiotics Development Program

PR-M03-18-NI-100
Clinical Trials

Clinical Trial Access to Expand Following Receipt of Additional Funding    

PAO-M03-18-NI-026
Influenza

Anti-Flu Drug Exploits Weakness in H3N2 Strain

PAO-M03-18-NI-021
Approval

European Commission Expands Marketing Approval for GSK’s Relvar Ellipta

PAO-M03-18-NI-013
Cell and Gene Therapy

Oxford BioMedica is Making Big Moves

PAO-M03-18-NI-012
Oncology

Charles River Laboratories Announces New Online Tool

PAO-M03-18-NI-003
Acquisition

Roche Pays $1.9 Billion to Acquire Flatiron Health

PAO-M02-18-NI-021
Licensing

Oxford BioMedica Completes Licensing Agreement with Bioverativ Inc.

PAO-M02-18-NI-019
FDA

Label Update Approved for Novartis’ Cosentyx

PAO-M02-18-NI-014
Fast Track

FDA Grants Fast Track Status to Takeda’s Zika Vaccine Candidate

PAO-M02-18-NI-003
Biosimilars

Novartis Makes More Biosimilar Moves

PAO-M01-18-NI-047
FDA

FDA and DoD Launch Joint Program to Accelerate Drug Development

PAO-M01-18-NI-043
Launch

GSK Launches Three-in-One HIV Pill in China

PAO-M01-18-NI-040
Expanded Capacity

Abbvie to Add Jobs in Ireland

PAO-M01-18-NI-037
Innovation

Harvard Researchers Use Chip Technology to Investigate New Anti-inflammatory Drugs

PAO-M01-18-NI-034
Partnership

Boehringer Ingelheim and Adimab Partner on Antibodies

PAO-M01-18-NI-030
Acquisition

Impact Biomedicines Acquired By Celgene

PAO-M01-18-NI-027
Expanded Capacity

Sharp Completes Pennsylvania Facility

PAO-M01-18-NI-022
M&A

Ignyta Snapped up by Roche

PAO-M01-18-NI-019
Big Data

Genomics Firm Attracts High-Tech Investments

PAO-M01-18-NI-015
CRISPR

Genetically Engineered Horses Could be a Reality

PAO-M01-18-NI-008
Research

Gilead Makes $100 Million Commitment to Fighting HIV/AIDs

PAO-M12-17-NI-038
Drug Development

Fucoidans Found in Seaweed Exhibit Promising Anticancer Properties

PAO-M12-17-NI-025
Abuse Deterrence

Generic Firms Developing Opioids with Abuse-Deterrent Properties Have New FDA Guidance to Follow

PAO-M12-17-NI-012
Regenerative Medicine

International Society for Cellular Therapy Supports New FDA Policy Framework for Regenerative Medicine

PAO-M12-17-NI-004
Non-Opioid

SiteOne Therapeutics Garners US Department of Defense Award

PAO-M11-17-NI-036
CRISPR

CRISPR Technology Could Enable New Treatments for Resistant Fungal Infections

PAO-M11-17-NI-006
Research

Don’t Be Scared: New Insight into How the Brain Learns Fear

PAO-M10-17-NI-040
Stem Cell Therapy

Aging Frailty Stem Cell Therapy Advances

PAO-M10-17-NI-025
Vaccine

Leprosy Vaccine in Human Trials

PAO-M10-17-NI-021
Vaccine

Merck, J&J Receive BARDA Funding for Ebola Vaccine Development

PAO-M10-17-NI-019
FDA Approval

FDA Approves New, Implantable Sleep Apnea Treatment

PAO-M10-17-NI-016
Drug Development

New Insulin Formulation Improves Mealtime Glycemic Control

PAO-M10-17-NI-011
Innovation

New Plant Will Supply Large Numbers of Genetically Modified Mosquitos

PAO-M10-17-NI-008
3D Bioprinting

Printing Human Organs — One Step Closer to Reality

PAO-M10-17-NI-004
Oncology

DNA Binding Protein May Increase Ovarian Cancer Survival

PAO-M09-17-NI-034
Biosimilar

FDA Approves First Biosimilar Treatment for Multiple Cancers

PAO-M09-17-NI-030
Innovation

FDA Green Lights Mobile App to Help Treat Drug Abuse

PAO-M09-17-NI-022
API

Becoming Bioavailable

MCO-M07-17-NI-021
Innovation

Women Gain New Control Over Mammogram Discomfort

PAO-M09-17-NI-016
FDA Approval

US Now Has an Approved Treatment for Chagas Disease

PAO-M09-17-NI-012
Drug Development

Novel Genetic Test Helps Confirm Opioid Addiction Risk

PAO-M09-17-NI-006
Oncology

Vitamin C: Prostate Cancer’s New Foe

PAO-M08-17-NI-039
Combination Therapy

Researchers at the University of Colorado Develop New Combination Hepatitis C Treatment

PAO-M08-17-NI-035
Research

Walgreens Introduces Center for Health & Wellbeing Research Website

PAO-M08-17-NI-031
FDA

FDA Makes Waves with Generic Approvals

PAO-M08-17-NI-024
Partnership

Academic-Industry Partnership Receives Funds to Develop Ebola Vaccine

PAO-M08-17-NI-021
NDA

Kite Submits Investigational New Drug Application for KITE-585

PAO-M08-17-NI-018
Microbiome

Personalized Genetic Screening Launches in the UK

PAO-M08-17-NI-014
Innnovation

Harvard Researchers Develop a New Adhesive That Adheres Even to Wet Wounds

PAO-M08-17-NI-009
Innovation

Joint Program Explores Devices to Treat Gastrointestinal Disease

PAO-M08-17-NI-004
Innovation

New Method for Detecting the Zika Virus Developed

PAO-M07-17-NI-033
Acquisition

Emergent BioSolutions Expands Its Drug Portfolio Through Two Acquisitions

PAO-M07-17-NI-030
Acquistion

Protein Sciences Snapped Up By Sanofi

PAO-M07-17-NI-024
ADC

Pfizer’s MYLOTARG Demonstrates Favorable Profile

PAO-M07-17-NI-022
Antibiotics

New Class of Antibiotics Looks Promising

PAO-M07-17-NI-017
Innovation

New Diagnostics Agent Designed to Identify Circulating Tumor Cells

PAO-M07-17-NI-011
Partnership

New Partnership to Tackle Challenging Infectious Diseases

PAO-M07-17-NI-005
FDA

FDA Moves to Improve Patient Access

PAO-M07-17-NI-004
Innovation

New Technology Allows Imaging of Complex Molecular Processes

PAO-M06-17-NI-023
Drug Delivery

Harvard University Researchers Develop Ultrasound/Nanoparticle Method for Targeted Delivery of Chemotherapeutics

PAO-M06-17-NI-015
Innovation

3D Patch Reduces Ischemia in Mouse Models

PAO-M06-17-NI-011
Collaboration

Tackling Breast Cancer With a New Type of Collaboration

PAO-M06-17-NI-010
Drug Delivery

Vetter and Microdermics Will Develop Microneedle Delivery Systems

PAO-M06-17-NI-008
Innovation

Merck Signs Global License Agreement for Potential Treatment for Alzheimer’s Disease

PAO-M06-17-NI-001
Biologics

Pharma Revs Up Cancer-Fighting CAR T-Cell Therapy

MCP-M06-17-NI-001
Innovation

From Blobs to Hearts: Understanding the 3D Bioprinting Revolution

PAP-Q2-17-TT-001
Clinical Trials

HIV Vaccine Demonstrates “Remarkable” Rates

PAO-M05-17-NI-039
FDA Approval

Fresh RA Treatment from Sanofi/Regeneron Approved

PAO-M05-17-NI-024
Innovation

Modeling Patient-Specific Kidney Diseases by Combining Engineered Stem Cells and Chip Technology

PAO-M05-17-NI-018
Acquisition

Allergan Zeltiq Aesthetics Acquisition Finalized

PAO-M05-17-NI-010
Pharma

Demand for Ovarian Cancer Drugs Forecast to Increase

PAO-M05-17-NI-005
Pharma

First On-Label Abuse-Deterrent Opioid Approved

PAO-M04-17-NI-026
CDMO

Cobra Biologics Invests in Gene Therapy

PAO-M04-17-NI-020
Regulatory

Advancing Clinical Trial Efficiency with Electronic Informed Consent

APR-M03-17-NI-001
CDMO

Catalent Completes Controlled-Temperature Capacity

PAO-M04-17-NI-012